Apolipoprotein E and atherosclerosis

Current Opinion in Lipidology

Volumn 11, Issue 3, 2000, Pages 243-251

  Curtiss, Linda K ^a   Boisvert, William A ^a  

^a SCRIPPS RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN A1; APOLIPOPROTEIN E; CHOLESTEROL; LIPOPROTEIN;

ATHEROSCLEROSIS; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL TRANSPORT; CHRONIC INFLAMMATION; FOAM CELL; HOMEOSTASIS; IMMUNE RESPONSE; INTIMA; MACROPHAGE; PRIORITY JOURNAL; REVIEW; T LYMPHOCYTE;

ANIMALS; APOLIPOPROTEINS E; ARTERIOSCLEROSIS; CHOLESTEROL; HOMEOSTASIS; HUMANS; INFLAMMATION;

EID: 0034087291     PISSN: 09579672     EISSN: None     Source Type: Journal    
DOI: 10.1097/00041433-200006000-00004     Document Type: Review

References (74)

1. 1 Davignon J, Cohn JS, Mabile L, Bernier L. Apolipoprotein E and atherosclerosis: insight from animal and human studies. Clin Chim Acta 1999; 286:115-143. A well written review that nicely complements animal studies on the protective role of apolipoprotein E. Special emphasis is placed on functional distinctions among the human apolipoprotein E isoforms.
2. 2 Ross R. Atherosclerosis is an inflammatory disease. Am Heart J 1999; 138:S419-S420. This valuable pioneering contribution to our understanding of the pathology of atherosclerosis, along with [3••], will stand the test of time.
3. 3 Ross R. Mechanisms of disease - atherosclerosis - an inflammatory disease. N Engl J Med 1999; 340:115-126. See [2••].
4. 4 Breslow JL. Mouse models of atherosclerosis. Science 1996; 272:685-688. A fine review of the important contributions that mutant, knockout and transgenic mouse models have made to our understanding of atherosclerosis.
5. 5 Moulton KS, Heller E, Konerding MA, Flynn E, Palinski W, Folkman J. Angiogenesis inhibitors endostatin or TNP-470 reduce intimal neovascularization and plaque growth in apolipoprotein E-deficient mice. Circulation 1999; 99:1726-1732. Reduction of intimai neovascularization will be an important drug target.
6. 6 Mahley RW. Apolipoprotein E: cholesterol transport protein with expanding role in cell biology. Science 1988; 240:622-630.
7. 7 Plump A. Atherosclerosis and the mouse: a decade of experience. Ann Med 1997; 29:193-198.
8. 8 Shimano H, Yamada N, Katsuki M, Yamamoto K, Gotoda T, Harada K, et al. Plasma lipoprotein metabolism in transgenic mice overexpressing apolipoprotein E. J Clin Invest 1992; 90:2084-2091.
9. 9 Huang YD, Schwendner SW, Rall Jr SC, Sanan DA, Mahley RW. Apolipoprotein E2 transgenic rabbits - Modulation of the type III hyperlipoproteinemic phenotype by estrogen and occurrence of spontaneous atherosclerosis. J Biol Chem 1997; 272:22685-22694.
10. 10 Zhang SH, Reddick RL, Piedrahita JA, Maeda N. Spontaneous hypercholesterolemia and arterial lesions in mice lacking apolipoprotein E. Science 1992; 258:468-472.
11. 11 Plump AS, Smith JD, Hayek T, Aalto-Setälä K, Walsh A, Verstuyft JG, et al. Severe hypercholesterolemia and atherosclerosis in apolipoprotein E-deficient mice created by homologous recombination in ES cells. Cell 1992; 71:343-353.
12. 12 Piedrahita JA, Zhang SH, Hagaman JR, Oliver PM, Maeda N. Generation of mice carrying a mutant apolipoprotein E gene inactivated by gene targeting in embryonic stem cells. Proc Natl Acad Sci USA 1992; 89:4471-4475.
13. 13 Hasty AH, Linton MF, Swift LL, Fazio S. Determination of the lower threshold of apolipoprotein E resulting in remnant lipoprotein clearance. J Lipid Res 1999; 40:1529-1538. This well documented study uses bone marrow transplantation to identify the activity of very small amounts of plasma apolipoprotein E.
14. 14 Shimano H, Yamada N, Katsuki M, Yamamoto K, Gotoda T, Harada K, et al. Plasma lipoprotein metabolism in transgenic mice overexpressing apolipoprotein E. Accelerated clearance of lipoproteins containing apolipoprotein B. J Clin Invest 1992; 90:2084-2091.
15. 15 Nikoulin IR, Curtiss LK. An apolipoprotein E synthetic peptide targets to lipoproteins in plasma and mediates both cellular lipoprotein interactions in vitro and acute clearance of cholesterol-rich lipoproteins in vivo. J Clin Invest 1998; 101:223-234. cholesterol lowering synthetic peptide mimic could provide an important therapeutic for hypertriglyceridemia and combined hyperlipidemia.
16. 16 Tsukamoto K, Tangirala R, Chun SH, Puré E, Rader DJ. Rapid regression of atherosclerosis induced by liver-directed gene transfer of ApoE in ApoE-deficient mice. Arterioscler Thromb Vasc Biol 1999; 19:2162-2170.
17. 17 Desurmont C, Caillaud JM, Emmanuel F, Benoit P, Fruchart JC, Castro G, et al. Complete atherosclerosis regression after human ApoE gene transfer in ApoE-Deficient/Nude mice. Arterioscler Thromb Vasc Biol 2000; 20:435-442.
18. 18 Linton MF, Hasty AH, Babaev VR, Fazio S. Hepatic apoE expression is required for remnant lipoprotein clearance in the absence of the low density lipoprotein receptor. J Clin Invest 1998; 101:1726-1736.
19. 19 Knouff C, Hinsdale ME, Mezdour H, Altenburg MK, Watanabe M, Quarfordt SH, et al. ApoE structure determines VLDL clearance and atherosclerosis risk in mice. J Clin Invest 1999; 103:1579-1586. An important study of the participation of the human apolipoprotein E isoforms that confirms a direct correlation between hepatic VLDL clearance rates and the extent of atherosclerosis.
20. 20 Boisvert WA, Spangenberg J, Curtiss LK. Treatment of severe hypercholesterolemia in apolipoprotein E-deficient mice by bone marrow transplantation. J Clin Invest 1995; 96:1118-1124.
21. 21 Linton MF, Atkinson JB, Fazio S. Prevention of atherosclerosis in apolipoprotein E-deficient mice by bone marrow transplantation. Science 1995; 267:1034-1037.
22. 22 Van Eck M, Herijgers N, Yates J, Pearce NJ, Hoogerbrugge PM, Groot PH, Van Berkel TJ. Bone marrow transplantation in apolipoprotein E deficient mice - effect of ApoE gene dosage on serum lipid concentrations, (β)VLDL catabolism, and atherosclerosis. Arterioscler Thromb Vasc Biol 1997; 17:3117-3126.
23. 23 Bellosta S, Mahley RW, Sanan DA, Murata J, Newland DL, Taylor JM, Pitas RE. Macrophage-specific expression of human apolipoprotein E reduces atherosclerosis in hypercholesterolemic apolipoprotein E-null mice. J Clin Invest 1995; 96:2170-2179.
24. 24 Thorngate FE, Rudel LL, Walzem RL, Williams DL. Low levels of extrahepatic non-macrophage apoE inhibit atherosclerosis without correcting hypercholesterolemia in apoE-deficient mice. Arterioscler Thromb Vasc Biol 2000; (in press).
25. 25 Huang YD, Liu XQ, Rall Jr SC, Taylor JM, Von Eckardstein A, Assmann G, Mahley RW. Overexpression and accumulation of apolipoprotein E as a cause of hypertriglyceridemia. J Biol Chem 1998; 273:26388-26393.
26. 26 Mensenkamp AR, Jong MC, Van Goor H, van Luyn MJ, Bloks V, Havinga R, et al. Apolipoprotein E participates in the regulation of very low density lipoprotein-triglyceride secretion by the liver. J Biol Chem 1999; 274:35711-35718. A paper emphasizing that apolipoprotein E regulates hepatic VLDL triglyceride secretion as well as hepatic mediating lipoprotein uptake.
27. 27 Fazio S, Babaev VR, Murray AB, Hasty AH, Carter KJ, Gleaves LA, et al. Increased atherosclerosis in mice reconstituted with apolipoprotein E null macrophages. Proc Natl Acad Sci USA 1997; 94:4647-4652.
28. 28 Boisvert WA, Curtiss LK. Elimination of macrophage-specific apolipoprotein E reduces diet-induced atherosclerosis in C57BL/6J male mice. J Lipid Res 1999; 40:806-813.
29. 29 Dueland S, Drisko J, Graf L, Machleder D, Lusis AJ, Davis RA. Effect of dietary cholesterol and taurocholate on cholesterol 7 alpha-hydroxylase and hepatic LDL receptors in inbred mice. J Lipid Res 1993; 34:923-931.
30. 30 Berliner JA, Navab M, Fogelman AM, Frank JS, Demer LL, Edwards PA, et al. Atherosclerosis: basic mechanisms: oxidation, inflammation, and genetics. Circulation 1995; 91:2488-2496.
31. 31 Boisvert WA, Spangenberg J, Curtiss LK. Role of leukocyte-specific LDL receptors on plasma lipoprotein cholesterol and atherosclerosis in mice. Arterioscler Thromb Vasc Biol 1997; 17:340-347.
32. 32 Linton MF, Babaev VR, Gleaves LA, Fazio S. A direct role for the macrophage low density lipoprotein receptor in atherosclerotic lesion formation. J Biol Chem 1999; 274:19204-19210.
33. 33 Hasty AH, Linton MF, Brandt SJ, Babaev VR, Gleaves LA, Fazio S. Retroviral gene therapy in ApoE-deficient mice - ApoE expression in the artery wall reduces early foam cell lesion formation. Circulation 1999; 99:2571-2576.
34. 34 Shimano H, Ohsuga J, Shimada M, Namba Y, Gotoda T, Harada K, et al. Inhibition of diet-induced atheroma formation in transgenic mice expressing apolipoprotein E in the arterial wall. J Clin Invest 1995; 95:469-476.
35. 35 Basu SK, Goldstein JL, Brown MS. Independent pathways for secretion of cholesterol and apolipoprotein E by macrophages. Science 1983; 219:871-873.
36. 36 Hara H, Yokoyama S. Interaction of free apolipoproteins with macrophages. Formation of high density lipoprotein-like lipoproteins and reduction of cellular cholesterol. J Biol Chem 1991; 266:3080-3066.
37. 37 Zhu YH, Bellosta S, Langer C, Bernini F, Pitas RE, Mahley RW, et al. Low-dose expression of a human apolipoprotein E transgene in macrophages restores cholesterol efflux capacity of apolipoprotein E-deficient mouse plasma. Proc Natl Acad Sci USA 1998; 95:7585-7590.
38. 38 Bodzioch M, Orso E, Klucken J, Langmann T, Bottcher A, Diederich W, et al. The gene encoding ATP-binding cassette transporter 1 is mutated in Tangier disease. Nat Genet 1999; 22:347-351. The identification of ABC1 as the sterol transporter defective in Tangier disease has altered our thinking on the roles of apolipoprotein A1 and apolipoprotein E in macrophage cholesterol efflux.
39. 39 Brooks-Wilson A, Marcil M, Clee SM, Zhang LH, Roomp K, Van Dam M, et al. Mutations in ABC1 in Tangier disease and familial high-density lipoprotein deficiency. Nature Genet 1999; 22:336-345. See [38••].
40. 40 Lawn RM, Wade DP, Garvin MR, Wang X, Schwartz K, Porter JG, et al. The Tangier disease gene product ABC1 controls the cellular apolipoprotein-mediated lipid removal pathway. J Clin Invest 1999; 104:R25-R31. See [38••].
41. 41 Owen JS. Role of ABC1 gene in cholesterol efflux and atheroprotection. Lancet 1999; 354:1402-1403. See [38••].
42. 42 Remaley AT, Rust S, Rosier M, Knapper C, Naudin L, Broccardo C, et al. Human ATP-binding cassette transporter 1 (ABC1): genomic organization and identification of the genetic defect in the original Tangier disease kindred. Proc Natl Acad Sci USA 1999; 96:12685-12690. See. [38••].
43. 43 Rust S, Rosier M, Funke H, Real J, Amoura Z, Piette JC, et al. Tangier disease is caused by mutations in the gene encoding ATP-binding cassette transporter 1. Nat Genet 1999; 22:352-355. See [38••]
44. 44 Zhang WY, Gaynor PM, Kruth HS. Apolipoprotein E produced by human monocyte-derived macrophages mediates cholesterol efflux that occurs in the absence of added cholesterol acceptors. J Biol Chem 1996; 271:28641-28646.
45. 45 Lin CY, Duan HW, Mazzone T. Apolipoprotein E-dependent cholesterol efflux from macrophages: kinetic study and divergent mechanisms for endogenous versus exogenous apolipoprotein E. J Lipid Res 1999; 40:1618-1626. This article contains a thorough discussion of the relative capacities of exogenous versus endogenous apolipoprotein E to participate in cellular cholesterol efflux.
46. 46 Zhao YW, Mazzone T. LDL receptor binds newly synthesized apolipoprotein E in macrophages: a precursor pool for apolipoprotein E secretion. J Lipid Res 1999; 40:1029-1035. This manuscript describes the existence of multiple potential interaction sites on macrophages for apolipoprotein E.
47. 47 Lucas M, Mazzone T. Cell surface proteoglycans modulate net synthesis and secretion of macrophage apolipoprotein E. J Biol Chem 1996; 271:13454-13460.
48. 48 Obunike JC, Pillarisetti S, Paka L, Kako Y, Butteri MJ, Ho YY, et al. The heparin-binding proteins apolipoprotein E and lipoprotein lipase enhance cellular proteoglycan production. Arterioscler Thromb Vasc Biol 2000; 20:111-118. It appears that apolipoprotein E not only binds to cell surface proteoglycans but also regulates their synthesis. Many apolipoprotein E functions may be mediated by this important interaction.
49. 49 Paka L, Kako Y, Obunike JC, Pillarisetti S. Apolipoprotein E containing high density lipoprotein stimulates endothelial production of heparin sulfate rich in biologically active heparin-like domains - a potential mechanism for the anti-atherogenic actions of vascular apolipoprotein E. J Biol Chem 1999; 274:4816-4823.
50. 50 Cullen P, Cignarella A, Brennhausen B, Mohr S, Assmann G, Von Eckardstein A. Phenotype-dependent differences in apolipoprotein E metabolism and in cholesterol homeostasis in human monocyte-derived macrophages. J Clin Invest 1998; 101:1670-1677.
51. 51 Benoit P, Emmanuel F, Caillaud JM, Bassinet L, Castro G, Gallix P, et al. Somatic gene transfer of human apoA-1 inhibits atherosclerosis progression in mouse models. Circulation 1999; 99:105-110.
52. 52 Pászty C, Maeda N, Verstuyft J, Rubin EM. Apolipoprotein A1 transgene corrects apolipoprotein E deficiency-induced atherosclerosis in mice. J Clin Invest 1994; 94:899-903.
53. 53 Rees D, Sloane T, Jessup W, Dean RT, Kritharides L. Apolipoprotein A-1 stimulates secretion of apolipoprotein E by foam cell macrophages. J Biol Chem 1999; 274:27925-27933.
54. 54 Boisvert WA, Black AS, Curtiss LK. ApoA1 reduces free cholesterol accumulation in atherosclerotic lesions of ApoE-deficient mice transplanted with ApoE-expressing macrophages. Arterioscler Thromb Vasc Biol 1999; 19:525-530. This report confirms that both apolipoprotein A1 and apolipoprotein E participate in cholesterol efflux from lesions in vivo.
55. 55 Witztum JL, Palinski W. Are immunological mechanisms relevant for the development of atherosclerosis? Clin Immunol Immunopathol 1999; 90:153-156. A very useful and clear argument for the participation of immune responses in atherosclerosis.
56. 56 Ross R. Cell biology of atherosclerosis. Annu Rev Physiol 1995; 57:791-804.
57. 57 Lutgens E, Daemen M, Kockx M, Doevendans P, Hofker M, Havekes L, et al. Atherosclerosis in APOE*3-Leiden transgenic mice: from proliferative to atheromatous stage. Circulation 1999; 99:276-283. This study confirms that lesion macrophages can both proliferate and undergo apoptosis depending upon the stage of the disease.
58. 58 Qiao JH, Tripathi J, Mishra NK, Cai Y, Tripathi S, Wang XP, et al. Role of macrophage colony-stimulating factor in atherosclerosis - studies of osteopetrotic mice. Am J Pathol 1997; 150:1687-1699.
59. 59 Smith JD, Trogan E, Ginsberg M, Grigaux C, Tian J, Miyata M. Decreased atherosclerosis in mice deficient in both macrophage colony-stimulating factor (op) and apolipoprotein E. Proc Natl Acad Sci USA 1995; 92:8264-8268.
60. 60 Murayama T, Yokode M, Kataoka H, Imabayashi T, Yoshida H, Sano H, et al. Intraperitoneal administration of anti-c-fms monoclonal antibody prevents initial events of atherogenesis but does not reduce the size of advanced lesions in apolipoprotein E-deficient mice. Circulation 1999; 99:1740-1746.
61. 61 Miyata M, Smith JD. Apolipoprotein E allele-specific antioxidant activity and effects on cytotoxicity by oxidative insults and beta-amyloid peptides. Nat Genet 1996; 14:55-61.
62. 62 Brand K, Mackman N, Curtiss LK. Interferon-gamma inhibits macrophage apolipoprotein E production by posttranslational mechanisms. J Clin Invest 1993; 91:2031-2039.
63. 63 Duan H, Li Z, Mazzone T. Tumor necrosis factor-α modulates monocyte/ macrophage apoprotein E gene expression. J Clin Invest 1995; 96:915-922.
64. 64 Dansky HM, Charlton SA, Harper MM, Smith JD. T and B lymphocytes play a minor role in atherosclerotic plaque formation in the apolipoprotein E-deficient mouse. Proc NatI Acad Sci USA 1997; 94:4642-4646.
65. 65 Daugherty A, Puré E, Delfel-Butteiger D, Chen S, Leferovich J, Roselaar SE, Rader DJ. The effects of total lymphocyte deficiency on the extent of atherosclerosis in apolipoprotein E - / - mice. J Clin Invest 1997; 100:1575-1580.
66. + T cells infiltrate lesions of apolipoprotein-E-deficient mice. Am J Pathol 1996; 149:359-366.
67. 67 Pepe MG, Curtiss LK. Apolipoprotein E is a biologically active constituent of the normal immunoregulatory lipoprotein, LDL-In. J Immunol 1986; 136:3716-3723.
68. 68 Kelly ME, Clay MA, Mistry MJ, Hsieh-Li H-M, Harmony JAK. Apolipoprotein E inhibition of proliferation of mitogen-activated T lymphocytes: Production of interleukin 2 with reduced biological activity. Cell Immunol 1994; 159:124-139.
69. 69 Gupta S, Pablo AM, Jiang XC, Wang N, Tall AR, Schindler C. IFN-gamma potentiates atherosclerosis in apoE knock-out mice. J Clin Invest 1997; 99:2752-2761.
70. 70 Zhou XH, Paulsson G, Stemme S, Hansson GK. Hypercholesterolemia is associated with a T helper (Th) 1 Th2 switch of the autoimmune response in atherosclerotic apoE knockout mice. J Clin Invest 1998; 101:1717-1725.
71. 71 Ishigami M, Swertfeger DK, Granholm NA, Hui DY. Apolipoprotein E inhibits platelet-derived growth factor-induced vascular smooth muscle cell migration and proliferation by suppressing signal transduction and preventing cell entry to G1 phase. J Biol Chem 1998; 273:20156-20161.
72. 72 Paka L, Goldberg IJ, Obunike JC, Choi SY, Saxena U, Goldberg ID, Pillarisetti S. Perlecan mediates the antiproliferative effect of apolipoprotein E on smooth muscle cells. An underlying mechanism for the modulation of smooth muscle cell growth? J Biol Chem 1999; 274:36403-36408. A thorough study of the antiproliferative activity of apolipoprotein E for smooth muscle cells. It definitively identifies that a specific increase in heparin sulfate proteoglycan mRNA leads to inhibition of cell proliferation.
73. 73 Riddell DR, Graham A, Owen JS. Apolipoprotein E inhibits platelet aggregation through the L-arginine:nitric oxide pathway - Implications for vascular disease. J Biol Chem 1997; 272:89-95.
74. 74 Riddell DR, Vinogradiv DV, Stannard AK, Chadwick N, Owen JS. Identification and characterization of LRP8 (apoER2) in human blood platelets. J Lipid Res 1999; 40:1925-1930.